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Dyslipidemia and inflammation may promote renal disease via
mechanisms of vascular endothelial cell dysfunction in type II
diabetes mellitus (DM). Sparse data, however, are available on
the relation of lipids and inflammatory biomarkers and
glomerular filtration rate (GFR) in type II DM. We performed a
cross-sectional study of 732 men with type II DM enrolled in
the Health Professionals’ Follow-Up Study. Plasma creatinine
was used to estimate GFR by the simplified Modification of
Diet in Renal Disease (MDRD) equation. In men with a GFR
o60 ml/min/1.73 m2, triglycerides, non-high-density
lipoprotein (HDL), apoprotein B, fibrinogen, soluble tumor
necrosis factor receptor (sTNFR-2) and vascular cell adhesion
molecule-1 (VCAM) were significantly higher when compared
to the referent group (GFRX90 ml/min/1.73 m2). In
multivariable logistic regression, those in the highest quartiles
of the following biomarkers had increased odds of having a
GFR o60 ml/min/1.73 m2 when compared to those in the
lowest quartiles: triglycerides (odds ratio (OR) 3.11; 95% CI,
1.52–6.36), fibrinogen (OR 5.40; 95% CI 2.14–13.65), sTNFR-2
(OR 8.34; 95% CI 3.50–19.88), and VCAM (OR 4.50; 95% CI
1.98–10.23). An inverse association was observed for HDL (OR
0.48; 95% CI 0.24–0.98). We found no association between
C-reactive protein and GFR. The results were similar when
creatinine clearance by Cockcroft–Gault was used to estimate
kidney function. We conclude that several potentially
modifiable lipid and inflammatory biomarkers are elevated in
the setting of moderately decreased GFR in men with type II
DM and may be the link between renal insufficiency and
increased risk for cardiovascular events in this population.
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Studies have generally suggested a positive association
between dyslipidemia and inflammation and end-stage renal
disease1–3 or advanced chronic kidney failure,4,5 but the
relation between these biomarkers and mild or moderate
renal dysfunction has not been well characterized, especially
in type II diabetes mellitus (DM). Type II DM is now
recognized as an inflammatory condition associated with
insulin resistance6 and abnormal endothelial vascular reac-
tivity.7 As the leading cause of kidney disease8 and an
important cause of cardiovascular disease (CVD) in the
Western world, type II DM is an increasingly prevalent
etiology of microvascular and macrovascular disease. A
chronic, systemic inflammatory state has been proposed to
underlie this increased risk for atherosclerotic disease,
including renal dysfunction and CVD; however, investiga-
tions have not focused on the relation between glomerular
filtration rate (GFR) and dyslipidemia or inflammatory
biomarkers in individuals with type II diabetes. Identification
of such serologic markers may reveal new approaches to the
prevention of progressive renal insufficiency and CVD in this
population.
We undertook a cross-sectional study to examine the
relation between renal function and (1) serum lipid levels
(total cholesterol, low-density lipoprotein (LDL), triglyce-
rides, high-density lipoprotein (HDL), lipoprotein-(a) (Lp
(a)), and apoprotein B (Apo B)) and (2) markers of
inflammation including C-reactive protein (CRP), fibrino-
gen, soluble tumor necrosis factor receptor (TNFR)-2,
intracellular adhesion molecule-1 (ICAM), and vascular cell
adhesion molecule-1 (VCAM) in 732 male subjects with type
II diabetes.
RESULTS
Demographic and clinical information for 732 men with type
II diabetes in 1994 is shown in Table 1. The mean age at
diabetes diagnosis was 54.1 years and the mean duration
from time of initial diabetes diagnosis was 11.3 years. In
this cohort, 54.2% had hypertension, 8.2% were taking
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angiotensin converting enzyme-inhibitor medication and
6.6% were taking a statin medication. Mean estimated GFR
was 79 ml/min/1.73 m2. When the variables in Table 1 were
stratified by estimated GFR levels, the men with GFR
o60 ml/min/1.73 m2 were older (68 vs 62.6 years,
Po0.001), had lower activity levels (21 vs 32.5 metabolic-
equivalent score (METS)/week, P¼ 0.02), a slightly lower
body mass index (BMI) (27.9 vs 28.3, P¼ 0.02), lower
HgbA1c (7.0 vs 7.7%, P¼ 0.008), were older at the time of
DM diagnosis (56 vs 52 years, Po0.001) and had higher
serum creatinine (sCr) (1.5 vs 0.8 mg/dl, Po0.0001) when
compared to those in the referent group (GFRX90 ml/min/
1.73 m2).
The median levels of measured lipid and inflammatory
biomarkers according to GFR category are shown in Table 2.
Levels of triglycerides, fibrinogen, soluble form of the TNFR
type 2 (sTNFR-2) and VCAM were consistently inversely
related to GFR. Whereas levels of total cholesterol, LDL, non-
HDL, and Apo B at lower GFR levels were higher than in the
referent group of GFRX90 ml/min/1.73 m2, these biomarker
levels did not consistently increase across the categories of
decreasing GFR.
By Spearman correlation, GFR was inversely and sig-
nificantly correlated with sTNFR-2 (r¼0.39, Po0.0001)
and VCAM (r¼0.23, Po0001). Statistically significant but
weaker associations were also observed between GFR and
total cholesterol (r¼0.09, P¼ 0.004), triglycerides
(r¼0.10, P¼ 0.01), non-HDL (r¼0.10, P¼ 0.008), Lp
(a) (r¼0.09, P¼ 0.02), Apo B (r¼0.13, P¼ 0.0006) and
CRP (r¼0.09, P¼ 0.02). The remaining biomarkers were
not found to be statistically associated with GFR by the
Spearman analysis.
We compared the differences in GFR between the highest
and lowest quartiles of each of these biomarkers. Multi-
variable adjusted linear regression revealed that the GFR was
significantly lower by 4.2 to 7.8 ml/min/1.73 m2 among
Table 1 | Demographic and clinical characteristics in 1994 of
732 type II diabetics in the Health Professional’s Follow-up
Study
Age (years) 65.577.9 (47–80)
Race
Caucasian 675 (92.2)
African-American 11 (1.5)
Other 13 (1.8)
No data 28 (3.8)
Hypertension 397 (54.2)
Weight (kg) 88.1716.2 (56.8–210.9)
BMI (kg/m2) 27.874.4 (18.3–56.5)
BMI categories (kg/m2)
o22 33 (4.5)
22–24.9 160 (21.9)
25–27.9 228 (31.1)
28–29.9 132 (18.0)
430 179 (24.5)
Activity (METS/week) 29.9733.2 (0–228.8)
Cigarette smoking
Current 42 (5.7)
Past 392 (53.6)
Never 261 (35.7)
No data 37 (5.0)
Age at diabetes diagnosis (years) 54.1+10.4 (26–78)
Duration of type II diabetes (years) 11.379.2 (0.1–43.8)
Measured HgbA1c (%) 7.571.6 (4.8–15.6)
ACE-inhibitor medication use 60 (8.2)
Statin medication use 48 (6.6)
Measured serum creatinine (mg/dl) 1.170.2 (0.4–2.9)
GFR (ml/min/1.73 m2) 79718 (23–183)
Results expressed as mean7s.d. (range 0–100%) or no. (%).
Hypertension was self-reported as ‘yes’ or ‘no’ on the 1994 questionnaire.
ACE, angiotensin-converting enzyme; GFR, glomerular filtration rate; BMI, body mass
index; HgbA1c, hemoglobin A1c.
Table 2 | Median levels of lipid and inflammatory biomarkers stratified by renal function
Calculated GFR (ml/min/1.73 m2)
Biomarker X90 (n=183) 75–89 (n=235) 60–74 (n=224) o60 (n=90)
Total cholesterol (mg/dl) 200 (137–275) 210 (147–279)** 209 (157–287)** 209 (148–282)
LDL (mg/dl) 123 (64–177) 131 (76–185)** 126 (69–193)* 122 (62–192)
HDL (mg/dl) 39 (25–61) 39 (28–63) 39 (26–65) 37 (25–57)
Non-HDL (mg/dl) 159 (103–235) 170 (111–233)** 68 (111–242)** 168 (115–239)*
TG (mg/dl) 157 (63–396) 165 (65–346) 168 (65–385) 182 (81–408)*
Lipoprotein (a) (mg/dl) 8.7 (0.7–64.4) 8.5 (0.8–78.8) 9.3 (0.7–75.8) 8.5 (0.7–61.1)
Apoprotein B (mg/dl) 99 (68–140) 106 (69–145)** 104 (69–150)** 107 (74–143)**
C-reactive protein (mg/dl) 0.17 (0.04–1.41) 0.17 (0.03–1.16) 0.18 (0.03–1.41) 0.21 (0.04–1.17)
Fibrinogen (mg/dl) 415 (301–676) 451 (301–686)* 484 (338–713)*** 513 (364–835)***
sTNFR-2 (pg/ml) 2525 (1631–4103) 2755 (1838–4433)** 3086 (2080–4598)*** 3918 (2173–5843)***
ICAM (ng/ml) 338 (232–541) 343 (240–522) 344 (230–499) 359 (256–482)
VCAM (ng/ml) 1254 (827–1977) 1340 (871–2014) 1427 (893–2141)*** 1540 (1073–2263)***
Results expressed as median (5–95th percentile values).
The bold italic values are statistically significant.
*P between 0.05 and 0.01, **P between 0.01 and 0.001, and ***Po0.001 for value compared to referent group (GFRX90 ml/min/1.73 m2) by Wilcoxon’s rank-sum test.
HDL, high-density lipoprotein; ICAM, intracellular adhesion molecule; LDL, low-density lipoprotein; TG, triglycerides; sTNFR-2, soluble tumor necrosis factor receptor-2; VCAM,
vascular cellular adhesion molecule.
Kidney International (2006) 69, 336–342 337
J Lin et al.: Biomarkers and renal function in type II diabetes o r i g i n a l a r t i c l e
those men in the highest quartiles of total cholesterol, non-
HDL, triglycerides and Apo B. Greater differences in GFR of
8.6 to 15.4 ml/min/1.73 m2 were noted in comparing the
extreme quartiles of fibrinogen, sTNFR-2 and VCAM
(Table 3). As adding angiotensin converting enzyme-
inhibitor and statin use did not significantly change the
coefficients, they were removed from the final model. We also
examined the data for associations between aspirin use
(reported as X2 times per week use on the 1994 Health
Professionals’ Follow-Up Study (HPFS) questionnaire) with
estimated GFR, and found no association between those who
reported use (n¼ 354 or 48% of the cohort) and GFRo60 ml/
min/1.73 m2 (odds ratio (OR) 1.08 [0.69, 1.68]). OR for indi-
vidual biomarkers and presence of GFRo60 ml/min/1.73 m2
did not change significantly when aspirin use was included
in the model.
Multivariable logistic regression analysis was used to
calculate the risk of having GFR of o60 ml/min/1.73 m2
when comparing the highest vs lowest quartile of lipid and
inflammatory biomarkers (Table 4). Those in the highest
quartiles of triglycerides, fibrinogen, sTNFR-2, ICAM, or
VCAM levels had 2.07-fold to 8.34-fold increased odds of
having a GFR o60 ml/min/1.73 m2 when compared to those
in the lowest quartiles of these biomarkers. Moreover, the test
for linear trend for these biomarkers was significant
(Pp0.01), with the exception of ICAM (P¼ 0.15). In
addition, logistic regression was performed to estimate odds
of GFR o60 ml/min/1.73 m2 per one standard deviation
(s.d.) unit change of each biomarker. The odds were
increased for triglycerides (OR 1.46 [1.18, 1.83]), fibrinogen
(OR 1.50 [1.20, 1.87]), sTNFR-2 (OR 2.84 [2.18, 3.71]) and
VCAM (OR 1.48 [1.20, 1.83]). Again, inclusion of angio-
tensin converting enzyme-inhibitor or statin medication use
did not significantly change the results. Using the waist-
to-hip ratio in place of BMI as a measure of adiposity in these
multivariable models resulted in a change of o10% for the
OR for each of the biomarkers.
When compared to those in the lowest quartile, those in
the highest quartile of HDL had decreased odds (OR 0.48
[0.24, 0.98]) of having GFR o60 ml/min/1.73 m2. The
association was marginally significant when HDL was
examined per s.d. (OR 0.79 [0.60, 1.04]). LDL was inversely
associated with GFR in the quartile age-adjusted analysis (OR
0.49 [0.25, 0.98]) and marginally significant in the multi-
variable model (OR 0.49 [0.24, 1.01]). On closer examination
of the data, only 14 individuals who were in the highest
quartile of LDL had a GFR of o60 ml/min/1.73 m2 as
compared to 27 individuals in the lowest quartile of LDL who
had a GFR of o60 ml/min/1.73 m2. In the multivariable
logistic regression model with one s.d. unit change as the
Table 4 | Logistic regression odds ratios for highest vs lowest quartile of lipid and inflammatory biomarkers for outcome of
calculated GFR o60 ml/min/1.73 m2
Biomarker Age-ajusted OR [95% CI] Multivariable OR [95% CI] P-for-trend across all quartiles
Total cholesterol (mg/dl) 0.83 [0.43, 1.61] 0.86 [0.43, 1.73] 0.69
LDL (mg/dl) 0.49 [0.25, 0.98] 0.49 [0.24, 1.01] 0.05
HDL (mg/dl) 0.43 [0.23, 0.82] 0.48 [0.24, 0.98] 0.07
Non-HDL (mg/dl) 1.14 [0.59, 2.22] 1.13 [0.56, 2.29] 0.98
TG (mg/dl) 2.68 [1.41, 5.09] 3.11 [1.52, 6.36] 0.01
Lipoprotein (a) (mg/dl) 1.02 [0.55, 1.87] 0.97 [0.51, 1.83] 0.90
Apoprotein B (mg/dl) 1.54 [0.79, 2.97] 1.48 [0.73, 2.98] 0.49
C-reactive protein (mg/dl) 1.24 [0.65, 2.35] 0.89 [0.44, 1.85] 0.99
Fibrinogen (mg/dl) 6.25 [2.56, 15.28] 5.40 [2.14, 13.65] 0.003
sTNFR-2 (pg/ml) 9.36 [4.07, 21.51] 8.34 [3.50, 19.88] o0.001
ICAM (ng/ml) 2.14 [1.09, 4.18] 2.07 [1.01, 4.26] 0.15
VCAM (ng/ml) 4.91 [2.21, 10.88] 4.50 [1.98, 10.23] 0.009
HDL, high-density lipoprotein; ICAM, intracellular adhesion molecule; LDL, low-density lipoprotein; TG, triglycerides; sTNFR-2, soluble tumor necrosis factor receptor-2; VCAM,
vascular cellular adhesion molecule.
Multivariable models are adjusted for age (continuous, years), hypertension (yes/no), BMI (continuous), cigarette smoking status (never, past, current), physical activity
(quartiles, METS/week), duration of type II DM (quartiles, years), measured HgbA1c (quartiles), cardiovascular disease (yes/no) and cancer (yes/no).
P-for-trend is testing for linear trend across all four quartiles of biomarker.
The bold italic values are statistically significant.
Table 3 | Difference in GFR (ml/min/1.73 m2) for those in the
highest vs the lowest quartile of lipid and inflammatory
biomarkers
Biomarker
Age-adjusted
[95% CI]
Multivariable*
[95% CI]
Total cholesterol (mg/dl) 4.2 [7.8, 0.5] 5.2 [8.9, 1.5]
LDL (mg/dl) 2.0 [5.8, 1.7] 2.8 [6.5, 1.0]
HDL (mg/dl) 2.4 [1.3, 6.1] 1.9 [2.0, 5.8]
Non-HDL (mg/dl) 5.9 [9.5, 2.2] 7.1 [10.8, 3.4]
TG (mg/dl) 7.8 [11.5, 4.2] 8.4 [12.2, 4.5]
Lipoprotein (a) (mg/dl) 1.1 [2.6, 4.7] 1.0 [2.7, 4.6]
Apoprotein B (mg/dl) 7.6 [11.3, 4.0] 8.0 [11.7, 4.3]
C-reactive protein (mg/dl) 3.1 [6.7, 0.6] 3.1 [7.2, 0.9]
Fibrinogen (mg/dl) 11.8 [15.3, 8.3] 11.2 [14.9, 7.5]
sTNFR-2 (pg/ml) 15.3 [18.9, 11.8] 15.4 [19.1, 11.7]
ICAM (ng/ml) 3.5 [71.7, 0.2] 3.3 [7.1, 0.5]
VCAM (ng/ml) 9.0 [12.6, 5.4] 8.6 [12.2, 4.9]
HDL, high-density lipoprotein; ICAM, intracellular adhesion molecule; LDL, low-
density lipoprotein; TG, triglycerides; sTNFR-2, soluble tumor necrosis factor
receptor-2; VCAM, vascular cellular adhesion molecule.
Multivariable models are adjusted for age (continuous, years), hypertension (yes/no),
BMI (continuous), cigarette smoking status (never, past, current), physical activity
(quartiles, mets/week), duration of type II DM (quartiles, years), measured HgbA1c
(quartiles), cardiovascular disease (yes/no) and cancer (yes/no).
The bold italic values are statistically significant.
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exposure, LDL was not significantly associated with GFR of
o60 ml/min/1.73 m2 (OR 0.88 [0.70, 1.12]).
We noted that VCAM was positively correlated with ICAM
(r¼ 0.53, Po0.0001) and sTNFR-2 (r¼ 0.57, Po0.0001). To
examine the independent associations, we also included two
correlated biomarkers (in quartiles) simultaneously in the
multivariable logistic regression model with the outcome of a
GFR o60 ml/min/1.73 m2. For example, when compared to
the lowest quartile, the highest quartile of VCAM was no
longer independently associated with GFR o60 ml/min/
1.73 m2 (P¼ 0.29) after adjusting for sTNFR-2 (OR 7.39
[2.81, 19.43]). When ICAM and VCAM were included in the
same model, the highest quartile of ICAM was no longer
associated with moderate renal dysfunction (P¼ 0.88),
whereas the highest quartile of VCAM remained significant
when compared to the lowest quartile (OR 4.62 [1.87,
11.43]).
DISCUSSION
We observed important associations between lipid and
inflammatory biomarkers and renal function in a cross-
sectional study of 732 men with type II diabetes. Limited data
are available regarding these biomarkers and renal function in
type II diabetes; this paper reports that several lipid and
inflammatory markers were independently associated with
reduced renal function in adult onset diabetes. Recent
investigations have reported that higher baseline levels of
sTNFR-2, IL-6, CRP,9 E-selectin, and ICAM10 are indepen-
dent predictors of incident type II diabetes in prospective
nested case–control analyses of the Nurses’ Health Study. The
accumulating evidence that chronic inflammation is a
harbinger of adult-onset diabetes raises provocative questions
of which, if any, of these same mechanisms lead to renal
dysfunction in diabetes and whether any of these mechanisms
also underlie nondiabetic nephropathy.
Overall, triglycerides, fibrinogen, sTNFR-2 and VCAM
levels were consistently and strongly inversely associated with
GFR in our study of men with type II diabetes, whereas HDL
was positively correlated with renal function and CRP was
not associated with GFR. These findings suggest that elevated
risk for macrovascular and microvascular disease in type II
diabetes may be due to progressive endothelial cell dysfunc-
tion and atherosclerosis mediated by elevated levels of these
biomarkers.
In secondary analyses of data from 1785 participants of
the Modification of Diet in Renal Disease (MDRD) study,
investigators have reported lower cholesterol levels at GFR
o25 ml/min/1.73 m2,11 but a direct comparison with our
findings of no association between total cholesterol and GFR
is difficult because the MDRD study excluded all but diet-
controlled diabetic subjects and encompassed a much lower
range of GFR than in our current study. Most previous
studies have found no relation between total cholesterol and
kidney dysfunction or dialysis-dependency.1,12,13 All of these
studies, however, had fewer than 100 subjects and excluded
diabetic subjects. In contrast, several of these same studies
reported higher triglyceride levels in subjects with kidney
dysfunction or those who were dialysis-dependent compared
to controls.1,12,14 Furthermore, a cross-sectional analysis of
5808 elderly participants in the Cardiovascular Heart Study
(CHS) also revealed higher triglycerides levels in those with
renal insufficiency (defined as sCr X1.5 mg/dl in men and
X1.3 mg/dl in women) compared to those without renal
insufficiency; participants with diabetes comprised only
12–14% of this cohort.4
We also noted that higher HDL levels were more common
in those without moderate renal insufficiency, defined as GFR
o60 ml/min/1.73 m2. This observation is consistent with
previous investigations demonstrating that those with kidney
dysfunction have 11–32% lower HDL levels.1,4,12,14 Our
findings are also consistent with a recent prospective analysis
of 4517 members of Physicians’ Health Study demonstrating
that those with an HDLo40 mg/dl at baseline had a twofold
higher risk of renal insufficiency (defined as Cr X1.5 mg/dl)
at 14 years of follow up.5 As all of these previously published
studies either excluded diabetics or hado15% diabetics, our
data confirm the inverse relation between HDL levels and
renal dysfunction in type II diabetes.
Previously published studies on the association between
LDL and presence of kidney disease have been mixed, with a
couple of investigations reporting a positive association,12,14
and others reporting no association.1,4,13 The finding that
LDL was inversely associated with GFR o60 ml/min/1.73 m2
was opposite to our expectations, especially because in our
cohort, the highest quartile of LDL was associated with a
2.8 ml/min/1.73 m2 difference in estimated GFR when
compared to the lowest quartile. On closer scrutiny, these
OR estimates were based on only a few patients who fell
within the highest quartile of LDL and had estimated GFR
o60 ml/min/1.73 m2. LDL was not statistically associated
with estimated GFR in any of our other analyses, and
therefore, we felt that this represented a chance finding.
We did not observe significant or consistent associations
between renal function and Lp(a) or Apo B. Whereas
previous publications have reported higher Lp (a) in subjects
with kidney disease, the studies either excluded individuals
with diabetes or included diabetics who had much lower
levels of renal function (creatinine clearance (CrCl) 2–19 ml/
min)15 than those in our current study. We found no
previously published literature on the relation between Apo B
and kidney function. In contrast, we found that fibrinogen
levels were consistently inversely correlated with GFR.
Fibrinogen has been noted to be positively associated with
albuminuria in individuals with diabetes16,17 and to be
elevated in subjects with renal insufficiency.1,2,4
We found no association between GFR and CRP levels.
Although some published investigations have found higher
CRP levels in those with chronic renal failure or on dialysis
compared to healthy controls, it should be noted that diabetic
subjects were excluded1–4 or comprised a minority (11–13%)
of the study subjects.18,19 Our results are consistent with
those recently published from the MDRD study (comprising
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of only 5% noninsulin-dependent diabetic subjects), which
reported that age-stratified CRP levels in subjects with mean
GFR 32.7 ml/min/1.73 m2 (range 12–55 ml/min/1.73 m2) ap-
proximated those in the general population as measured in
the National Health and Nutrition Examination Survey III
study.20 Of note, two studies looking at CRP specifically in
people with diabetes have reported an association with
albuminuria and higher CRP levels, but did not address the
relation between CRP and renal function.16,17
Tumor necrosis factor alpha (TNF-a) is an inflammatory
cytokine with a short plasma half-life; therefore, sTNFR-2 is
frequently used as a more stable surrogate marker. Because
TNF-a is reported to be elevated in obese subjects,21 our
multivariable models included BMI, and we observed a
strong and consistent inverse association between sTNFR-2
and renal function. One small study of 64 predialysis patients
(mean sCr 6.0 mg/dl) also reported a twofold elevation in
TNF-a levels when compared with 40 healthy controls.2 The
inverse association between GFR and sTNFR-2 may result
from decreased clearance of this inflammatory cytokine in
renal dysfunction as previously reported in a bilateral
nephrectomized mouse model.22
We found no consistent relation between ICAM and GFR.
Higher ICAM levels have been reported in dialysis-dependent
subjects,1,3,23 and in small studies of subjects with advanced
renal dysfunction (mean sCr 6.0 mg/dl, range 1.3–6.7 mg/
dl).2,23 The cross-sectional CHS investigation reported 6%
higher ICAM levels in those with renal dysfunction compared
with those without.4 These CHS results may not be
generalizable to subjects with better preserved kidney
function as the mean CrCl in the renal dysfunction group
was 39 ml/min, which is lower than that in our current
cohort where only two subjects had a GFR o30 ml/min/
1.73 m2. No previously published reports on ICAM and
higher GFR levels were found.
We observed a strong and consistent inverse association
between VCAM levels and GFR. Like ICAM, elevated VCAM
levels have been observed in obese women21 and in dialysis-
dependent subjects.1,3,23 Although one prospective observa-
tional study of 363 type II diabetics reported a 1.5–2.0
increased relative risk for mortality in those with higher
VCAM levels, it did not examine its relation to GFR.17
Interestingly, although both VCAM and ICAM expression are
upregulated in inflammatory states, ICAM is constitutively
expressed at low levels on normal endothelial cells,24 and
VCAM appears to be a more important factor in the
initiation of atherosclerotic lesions.25 Our study found an
inverse relation between VCAM and renal function, which
may suggest an intensifying atherosclerotic process in those
with decreased GFR, in a large cohort of people with type II
diabetes.
By entering combinations of two significant biomarkers
simultaneously into regression models, we observed that
VCAM was not an independent predictor of GFR o60 ml/
min/m2 after controlling for sTNFR-2, suggesting that these
molecules may be involved in the same inflammatory
pathway. TNF-a infusion stimulates VCAM expression in
the endothelial cells from a rabbit aorta,26 but we found no
clinical human studies examining this relation.
Limitations to our study include the cross-sectional
design, which limits conclusions about mechanism or
temporal relation. A prospective study would provide
information about how these biomarkers may change with
declining kidney function over time; however, the lack of
previous data on how these biomarkers relate to GFR in
diabetes makes these findings informative. The rare use of
angiotensin converting enzyme-inhibitor and statin medica-
tions in 1994 in this cohort may limit the generalizability of
our results under current medical practices as these therapies
are much more prevalent today in diabetics. Importantly,
however, our study allows for a purer physiological
examination of the association between GFR and biomarkers,
because angiotensin converting enzyme inhibitors can elevate
sCr, and statins usually lower blood lipids. Unfortunately, no
information is available on measured albuminuria, which is
considered a marker for generalized endothelial vascular
injury in the kidney or nephrotic range proteinuria, which
can increase total cholesterol and LDL. Lastly, renal function
was estimated from creatinine-based prediction equations as
direct radio-isotope GFR measurements would have been
difficult and impractical in this cohort of 4700 men.
Estimated CrCl using the Cockcroft–Gault formula has been
shown to be as accurate as CrCl measured by 24 h urine
collections in diabetics.27 Whereas we chose to present the
kidney function as GFR estimated by the simplified MDRD
equation, the results were very similar when CrCl by
Cockcroft–Gault was invoked. There is a growing literature
on underestimation of true measured GFR by the MDRD
equations in people with sCr values in the normal range.28–30
We used categories of estimated GFR rather than GFR as a
continuous variable, and therefore the relative association
between these biomarkers and estimated GFR o60 ml/min/
1.73 m2 should not be influenced by a systematic bias in the
estimation equation. Moreover, the associations seen were
consistent whether GFR was a continuous (Table 3) or a
categorical (Tables 2 and 4) variable. The relatively high
coefficients of variation of plasma creatinine in this study
would presumably result in random misclassification and
bias the findings towards the null.
In conclusion, triglycerides, fibrinogen, sTNFR-2 and
VCAM levels are inversely associated with GFR in a large
cohort of men with type II diabetes, while HDL is positively
correlated with renal function. The potential impact of drug
therapies on altering these biomarkers and thereby slowing
the progression of renal dysfunction is of great clinical
interest and importance. Further investigation is also needed
to determine whether the elevated levels of triglycerides and
inflammatory biomarkers are due to increased production,
decreased degradation, decreased excretion or some combi-
nation in the setting of declining renal function. Nevertheless,
an exciting new and more focused picture of dyslipidemia
and chronic endothelial inflammation is emerging as the
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potential mechanism behind the manifold risk of renal
dysfunction and CVD in individuals with type II diabetes.
MATERIALS AND METHODS
Source population
The HPFS was established in 1986 when 51 529 US male health
professionals, aged 40–75 at study initiation, returned a mailed
questionnaire providing information about diet, lifestyle factors and
medical history.31 Participants were mailed follow-up questionnaires
every 2 years to update information. In 1993–1994, blood samples
were collected and frozen (1301C) from a subset of these
participants (n¼ 18 159), as previously described.32 Internal review
has shown no demographic or clinical differences at baseline
between men who provided blood samples and those who did not.
DM was first identified by self-report on a biennial questionnaire
and confirmed by a Diabetes Supplemental Questionnaire (DSQ) in
2000; the validity of the DSQ in confirming DM has been
demonstrated in the HPFS cohort.33 The HPFS DM blood cohort
consists of 1000 men (a number occurring by chance), with
confirmed diabetes at baseline or during follow-up through 1998,
who provided a blood sample in 1993–1994. Exclusion criteria for
the current analyses were as follows: (a) age of onset of DMp25
years of age (to attempt to restrict the study to type II DM) (n¼ 31),
(b) subjects with a reported date of DM diagnosis after the date of
blood draw (n¼ 225), (c) participants who reported on the DSQ
that they were on dialysis (n¼ 9) or had a kidney transplant (n¼ 3).
After these exclusions, 732 subjects were available for analysis.
Assessment of serum lipids, inflammatory biomarkers,
hemoglobin A1c and creatinine
Serum lipids, inflammatory biomarkers, hemoglobin A1c and
creatinine were measured at the Boston Children’s Hospital
Laboratory (Nader Rifai, Director). Non-HDL cholesterol was
defined as the difference between total cholesterol and HDL
cholesterol. Hypercholesterolemia was defined as total cholesterol
X200 mg/dl. The specific methodology for these assays have been
previously reported.34 The coefficients of variation for all of the
assays were p8% except for (a) CRP (14.8%) and (b) creatinine
(22.2%).
Assessment of renal function
Renal function was estimated by the simplified MDRD equation
where GFR (ml/min/1.73 m2)¼ 186 [PCr (mg/dl)]1.154
[Age]0.203 [1.21 if subject is black]35 and the Cockcroft–Gault
equation where CrCl¼ ([140age (years)weight (kg)]/Pcr 72).36
Because the direction and magnitude of associations between
biomarkers and either MDRD-GFR or CrCl were consistently
very similar, only the data using the MDRD-GFR are reported here.
No data on proteinuria were available as no urine has been collected
from this cohort.
Assessment of covariates
Race and height were initially reported on the 1986 questionnaire.
Weight, smoking status, hypertension and medication use from the
1994 questionnaire were used. BMI in 1994 was calculated by
[weight (kg)/(height (m))2]. A weekly METS was calculated from
the physical activity section on the 1994 biennial questionnaire.
CVD (myocardial infarction, coronary artery bypass grafting or
angina) (n¼ 194)37 and cancer diagnoses (n¼ 31)38,39 have also
been previously validated in this cohort.
Statistical analyses
Most biomarkers were not normally distributed, therefore lipid and
inflammatory biomarker levels stratified by level of GFR are
reported as medians (5–95th percentile range). The Wilcoxon
signed-rank test was used for intergroup comparisons with GFR
X90 ml/min/1.73 m2 as the referent group. Spearman correlation
coefficients were calculated for each pair of biomarkers.
The dependent variable of estimated GFR was normally
distributed. Linear regression was used to assess the difference in
renal function across biomarker quartiles. Logistic regression was
used to calculate ORs for GFR o60 ml/min/1.73 m2. Multivariable
models were adjusted for age (continuous, years), hypertension (yes/
no), BMI (continuous), cigarette smoking status (never, past,
current), physical activity (quartiles, METS/week), duration of type
II DM (quartiles, years), measured hemoglobin A1c (quartiles),
CVD (yes/no) and cancer (yes/no). All analyses were performed with
SAS software, version 8.2 (SAS Institute, Inc., Cary, NC, USA).
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